Primary myelofibrosis

Board exam relevance: in 1 of more than 100 exam reports · rank 181
Synonyms
myelofibrosis, idiopathic myelofibrosis, agnogenic myeloid metaplasia, bone marrow fibrosis
Specialty
Internal medicine · Haematology & oncology
Images
Blood smear & cytology 1 · Histology 1
Last updated
10/2026 · Dr. Pascal Bafteh
Contents
  1. Images (2)
  2. Definition
  3. Occurrence & epidemiology
  4. Aetiopathogenesis
  5. Clinical features
  6. Diagnosis
  7. Treatment principles
  8. Keep learning in the app
  9. Further reading (open access)
  10. Cross-references

Images (2)

Primary myelofibrosis – Blood smear: numerous teardrop cells (dacrocytes), typical of myelofibrosisBlood smear & cytology
Blood smear: numerous teardrop cells (dacrocytes), typical of myelofibrosisImage: Paulo Henrique Orlandi Mourao, “Teardrop Cells smear 2009-09-22” (Wikimedia Commons) · CC BY-SA 3.0 · Source
Primary myelofibrosis – histology: Bone marrow biopsy, silver (reticulin) stain: dense network of increased, thickened reticulin fibers in myelofibrosisHistology
Bone marrow biopsy, silver (reticulin) stain: dense network of increased, thickened reticulin fibers in myelofibrosisImage: Ed Uthman from Houston, TX, USA, “Myelofibrosis, Reticulin Stain (6032644716)” (Wikimedia Commons) · CC BY 2.0 · Source
1 / 2

Definition

Primary myelofibrosis (PMF) is a chronic myeloproliferative neoplasm with bone marrow fibrosis, extramedullary hematopoiesis (mainly in the spleen), splenomegaly, and anemia with nucleated red cell precursors and teardrop-shaped red cells in the blood. The WHO classification distinguishes prefibrotic from fibrotic PMF. Secondary myelofibrosis in other diseases is to be distinguished.

Occurrence & epidemiology

Incidence peaks between 50 and 70 years of age; men are affected more often.

Aetiopathogenesis

The starting point is neoplastic transformation of a pluripotent hematopoietic stem cell with proliferation of atypical megakaryocytes and granulocytes. The progeny of the clone stimulate non-neoplastic fibroblasts to produce excess collagen, resulting in reticulin and collagen fibrosis and osteosclerosis. Driver mutations affect JAK2, CALR, or MPL; rarely none is detectable (triple-negative PMF). Further mutations, particularly in TET2, ASXL1, and DNMT3A, are found in many MPN; less common additional mutations (e.g., in SRSF2, U2AF1, EZH2) are more frequent in PMF than in PV and ET.

Secondary myelofibrosis occurs, among others, with bone marrow metastases, lymphomas, leukemias, multiple myeloma, tuberculosis, benzene or radiation exposure, and following PV or ET.

Clinical features

  • Often asymptomatic for a long time.
  • Anemia with fatigue and reduced exercise tolerance, increasing over time.
  • Splenomegaly, sometimes with splenic infarcts; hepatomegaly in some patients.
  • In later stages, malaise, weight loss, and fever.
  • Lymphadenopathy is rare.
  • Extramedullary hematopoiesis can impair the function of the affected organ.
  • Over time, bone marrow failure with thrombocytopenia; transition to acute leukemia is possible.

Diagnosis

  • Blood count and smear: anemia; poikilocytosis with teardrop-shaped red cells (dacrocytes); leukoerythroblastic picture with nucleated red cell precursors and immature granulocytes; white cell count usually increased but variable; platelets initially high, normal, or low, later usually decreased.
  • LDH frequently elevated.
  • Bone marrow biopsy: fibrosis on reticulin or trichrome staining; atypical megakaryocytes.
  • Molecular genetics: detection of a JAK2, CALR, or MPL mutation confirms the diagnosis; extended gene sequencing (myeloid panel) detects additional mutations.
  • Exclusion of secondary causes of myelofibrosis.

Treatment principles

  • Treatment depends on risk profile and symptoms; allogeneic stem cell transplantation is the only curative option for suitable patients.
  • JAK inhibitors are used to control splenomegaly and constitutional symptoms.
  • Anaemia is managed supportively, for example with transfusions and iron chelation where needed; asymptomatic low-risk patients are often observed initially.

Specific treatment regimens with drugs and doses are covered in the InnereFuchs app.

Keep learning in the app

In the InnereFuchs app you can learn Primary myelofibrosis with flashcards, exam questions and image tasks (ECG, chest X-ray, ultrasound, lab values) – free, in your browser or as an app.

Open in browser  About InnereFuchs →

Further reading (open access)

  1. MSD Manual Professional: Primary Myelofibrosis (PMF)
  2. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
  3. MSD Manual Professional: Overview of Myeloproliferative Neoplasms

Cross-references

Keep learning

Keep learning with flashcards, exam questions and spot diagnoses in the InnereFuchs app – free, in your browser or as an app.

Related pages: Anemia (classification and work-up) · Hemolytic anemias · Acute myeloid leukemia (AML)

Note: Learning content for medical education – not a treatment recommendation and no substitute for diagnosis or treatment decisions in individual cases. Treatment and management are deliberately not covered on this page.